FDA Accepts COMP360 Psilocybin IND Application for PTSD Treatment as Compass Pathways Advances Late-Stage Clinical Development
核心洞察
The FDA has accepted Compass Pathways' Investigational New Drug application for COMP360, enabling initiation of a Phase 2b/3 clinical trial in patients with post-traumatic stress disorder (搜索).
The multicenter study will evaluate two 25 mg doses of COMP360 versus 1 mg control doses, with the primary endpoint measuring CAPS-5 (搜索) total severity score changes at week 8.
Previous Phase 2 data showed COMP360 demonstrated 9.9 and 29.5 point reductions in CAPS-5 (搜索) scores at weeks 4 and 12, respectively, with no treatment-emergent serious adverse events.
The US Food and Drug Administration (搜索) has accepted Compass Pathways' Investigational New Drug application for COMP360, a synthetic psilocybin treatment, enabling the company to initiate a Phase 2b/3 clinical trial in patients with post-traumatic stress disorder (搜索). The acceptance marks a significant milestone for what could become the first FDA-approved psilocybin-based therapy for PTSD (搜索), addressing a critical unmet medical need affecting approximately 13 million adults in the US.
Late-Stage Trial Design and Endpoints
The upcoming Phase 2b/3 study (COMP202) will be a multicenter, randomized, double-blind, controlled trial with an open-label extension. The study comprises two distinct parts designed to evaluate both short-term efficacy and long-term safety of COMP360 in PTSD (搜索) patients.
Part A represents the 12-week blinded portion, comparing two administrations of COMP360 25 mg versus two doses of 1 mg, with the second administration occurring approximately 4 weeks after the first. The primary efficacy endpoint will measure the change from baseline in Clinician-Administered PTSD (搜索) Scale for DSM-5 (CAPS-5 (搜索)) total severity score at week 8.
Part B consists of a 40-week open-label follow-up to evaluate long-term safety and efficacy. Eligible participants will receive a single open-label retreatment with COMP360 25 mg. In both study parts, COMP360 may be administered adjunctively to a single permitted oral antidepressant.
Promising Phase 2 Safety and Efficacy Data
The regulatory acceptance builds on encouraging results from a previous Phase 2 open-label study (NCT05312151) that included 22 patients with severe PTSD (搜索). Participants received one 25 mg COMP360 dose along with psychological support, and the study met both its primary safety and secondary efficacy endpoints.
The efficacy results demonstrated substantial symptom improvements, with CAPS-5 (搜索) total score reductions of 9.9 points at week 4 and 29.5 points at week 12. Additionally, participants showed meaningful functional improvements, with Sheehan Disability Scale total score reductions of 11.7 and 14.4 points at weeks 4 and 12, respectively.
From a safety perspective, the study reported no treatment-emergent serious adverse events. The most commonly reported adverse events were headache (50%), nausea (36.4%), crying (27.3%), and fatigue (27.3%). While suicidal ideation was reported in two patients with a history of suicidality, both cases resolved during the study, with the first resolving on the day of administration.
Addressing Critical Unmet Medical Need
PTSD (搜索) represents one of the most challenging mental health conditions, characterized by symptoms including intrusive memories, avoidance behaviors, negative shifts in mood and cognition, and heightened arousal. The condition affects approximately 5% of adults in the US annually, with certain populations including veterans, first responders, and abuse survivors at elevated risk.
Currently, only two FDA-approved medications exist for PTSD (搜索) treatment, highlighting the limited pharmacological landscape and urgent need for innovative therapeutic approaches. Individuals with PTSD frequently experience comorbid conditions including depression (搜索), anxiety disorders (搜索), and substance use disorders (搜索), along with significantly increased suicide risk.
"PTSD (搜索) is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options," said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. "We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to transform the treatment landscape for PTSD and bring hope to those who need it most."
Breakthrough Therapy Designation and Commercial Preparations
COMP360 is an investigational synthetic psilocybin treatment with potential for being a first-in-class therapy. The compound has already received breakthrough therapy designation from the FDA for treatment-resistant depression (搜索) (TRD (搜索)), with data from Phase 3 trials COMP006 and COMP005 for TRD expected in early first and third quarters of 2026, respectively.
Compass Pathways continues advancing commercial preparations to be launch-ready by the end of the year for COMP360 in treatment-resistant depression (搜索). The company recently held a positive Type B meeting with the FDA in September 2025 to discuss NDA submission strategy for COMP360 in TRD (搜索) and potential acceleration scenarios, including rolling submission.
"We enter 2026 with excitement and strong momentum, driving innovation to address critical needs in both PTSD (搜索) and TRD (搜索)," said Kabir Nath, Chief Executive Officer at Compass Pathways. "As our commercialization plans advance, our focus is on ensuring seamless access to COMP360 for patients living with TRD, if approved. We look forward to continuing our close collaboration with the FDA and remain committed to generating robust clinical evidence with scientific rigor as we move into this next chapter."
Financial Positioning and Strategic Collaborations
To support its advancing clinical programs, Compass Pathways recently amended its existing term loan facility with Hercules Capital, increasing the overall size to up to $150 million. The amendment extends the interest-only period until at least January 5, 2029, with further extensions subject to achieving specified milestones, and extends the maturity date to January 5, 2031.
The company's strategic collaborations continue yielding valuable insights about COMP360 psilocybin treatment integration into various healthcare settings. Compass recently added Radial (搜索), a national network of clinics delivering interventional, evidence-based treatments for mental health conditions, as its seventh collaboration partner.